Thermo Fisher Scientific CARD10 Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

1:1,000-1:3,000

-

Immunohistochemistry (Paraffin) (IHC (P))

1:50-1:200

-

Immunocytochemistry (ICC/IF)

1:100-1:500

-

Product Specifications

Species Reactivity

Human, Mouse

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

A synthesized peptide derived from human CARD10(Accession Q9BWT7), corresponding to amino acid residues T68-Q118. if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:CARD10,uniProtId:Q9BWT7-1,ncbiNodeId:9606,antigenRange:68-118,antigenLength:1032,antigenImageFileName:PA5-103188_CARD10_Q9BWT7-1_Rabbit.svg,antigenImageFileNamePDP:PA5-103188_CARD10_Q9BWT7-1_Rabbit_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.4, with 50% glycerol

Contains

0.02% sodium azide

Storage conditions

-20°C

Shipping conditions

Wet ice

RRID

AB_2852556

Product Specific Information

Antibody detects endogenous levels of total CARD10.

Target Information

CARMA proteins belong to the membrane-associated guanylate kinase-like (MAGUK) family of proteins that can function as molecular scaffolds that assist assembly of signal transduction molecules. CARMA1, CARMA2, and CARMA3 share high degrees of sequence and functional homology, but their tissue-specific distribution suggests that they serve distinct biological functions in different cell types. As with CARMA1, the CARD domain of CARMA3 has been shown to specifically interact with BCL10, a protein known to function as a positive regulator of cell apoptosis and NF-Kappa-B activation. When expressed in cells, this protein binds to BCL10 and activates NF-Kappa-B Recent experiments have shown that CARMA3 is required for EGF-induced NF-Kappa-B activation and contributes to tumor growth in vivo, suggesting that CARMA3 may serve as a new therapeutic target for the treatment of EGFR-driven tumors.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.